Characterization of Salmonella spp. mutants with reduced fluoroquinolone susceptibility: Importance of efflux pump mechanisms

Chemotherapy

Volumn 51, Issue 1, 2005, Pages 40-43

  Cebrián, Laura ^a   Rodríguez, Juan Carlos ^a   Escribano, Isabel ^a   Royo, Gloria ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Fluoroquinolones; Pump efflux; Salmonella mutants

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; DIPEPTIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); NALIDIXIC ACID; PHENYLALANINE ARGININE BETA NAPHTHYLAMIDE; PHENYLALANINE ARGININE BETA-NAPHTHYLAMIDE; QUINOLONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM MUTANT; DRUG ELIMINATION; DRUG STRUCTURE; DRUG TRANSPORT; EFFUSION; NONHUMAN; PRIORITY JOURNAL; SALMONELLA; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MUTATION; PHYSIOLOGY; SALMONELLOSIS;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DIPEPTIDES; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NALIDIXIC ACID; SALMONELLA; SALMONELLA INFECTIONS;

EID: 21344443422     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084417     Document Type: Article

References (21)

1. 2-dependent bactericidal mechanisms. Chemotherapy 1999;45:268-276.
2. Graninger W, Zedtwitz-Liebenstein K, Laferl H, Burgmann H: Quinolones in gastrointestinal infections. Chemotherapy 1996;42:43-53.
3. Threlfall EJ, Fisher IS, Berghold C, Gerner-Smidt P, Tschape H, Cormican M, Luzzi I, Schnieder F, Wannet W, Machado J, Edwards G: Antimicrobial drug resistance in isolates of Salmonella enterica from cases of salmonellosis in humans in Europe in 2000: Results of international multi-centre surveillance. Euro Surveill 2003;8:41-45.
4. Stock I, Wiedemann B: Natural antibiotic susceptibility of Salmonella enterica strains. Int J Antimicrob Agents 2000;16:211-217.
5. Witte W: Ecological impact of antibiotic use in animals on different complex microflora: Environment. Int J Antimicrob Agents 2000;14:321-325.
6. Moreno MA, Dominguez L, Teshager T, Herrero IA, Porrero MC: Antibiotic resistance monitoring: The Spanish programme. The VAV Network. Red de Vigilancia de Resistencias Antibioticas en Bacterias de Origen Veterinario. Int J Antimicrob Agents 2000;14: 285-290.
7. Martel JL, Tardy F, Brisabois A, Lailler R, Coudert M, Chaslus-Dancla E: The French antibiotic resistance monitoring programs. Int J Antimicrob Agents 2000;14:275-283.
8. Cebrián L, Sirvent E, Rodriguez JC, Ruiz M, Royo G: Characterisation of Salmonella sp. mutants following exposure to various fluoroquinolones. Int J Antimicrob Agents 2003;21:134-139.
9. Ribera A, Ruiz J, Jiménez de Anta MT, Vila J: Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother 2002;49:697-702.
10. Piddock LJ, Ricci V, McLaren I, Griggs DJ: Role of mutation in the gyrA and parC genes of nalidixic-acid-resistant salmonella serotypes isolated from animals in the United Kingdom. J Antimicrob Chemother 1998;41:635-641.
11. Piddock LJ: Fluoroquinolone resistance in Salmonella serovars isolated from humans and food animals. FEMS Microbiol Rev 2002;26:3-16.
12. Giraud E, Brisabois A, Martel JL, Chaslus-Dancla E: Comparative studies of mutations in animal isolates and experimental in vitro and in vivo selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field. Antimicrob Agents Chemother 1999;43:2131-2137.
13. Ruiz J, Castro D, Goni P, Santamaria JA, Borrego JJ, Vila J: Analysis of the mechanism of quinolone resistance in nalidixic-acid-resistant clinical isolates of Salmonella serotype typhimurium. J Med Microbiol 1997;46:623-628.
14. Baucheron S, Imberechts H, Chaslus-Dancla E, Cloeckaert A. The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204. Microb Drug Resist 2002;8:281-289.
15. Giraud E, Cloeckaert A, Kerboeuf D, Chaslus-Dancla E: Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother 2000;44:1223-1228.
16. Piddock LJ, Ricci V, McLaren I, Griggs DJ: Role of mutation in the gyrA and parC genes of nalidixic-acid-resistant salmonella serotypes isolated from animals in the United Kingdom. J Antimicrob Chemother 1998;41:635-641.
17. Liebana E, Clouting C, Cassar CA, Randall LP, Walker RA, Threlfall EJ, Clifton-Hadley FA, Ridley AM, Davies RH: Comparison of gyrA mutations, cyclohexane resistance, and the presence of class I integrons in Salmonella enterica from farm animals in England and Wales. J Clin Microbiol 2002;40:1481-1486.
18. Hansen H, Heisig P: Topoisomerase IV mutations in quinolone-resistant salmonellae selected in vitro. Microb Drug Resist 2003;9:25-32.
19. Soto SM, Ruiz J, Mendoza MC, Vila J: In vitro fluoroquinolone-resistant mutants of Salmonella enterica serotype enteritidis: Analysis of mechanisms involved in resistance. Int J Antimicrob Agents 2003;22:537-540.
20. Medders WM, Wooley RE, Gibbs PS, Shotts EB, Brown J: Mutation rate of a vian intestinal coliform bacteria when pressured with fluoroquinolones. Avian Dis 1998;42:146-153.
21. Aarestrup FM, Wiuff C, Molbak K, Threlfall RI: Is it time to change fluoroquinolone breakpoints for Salmonella spp? Antimicrob Agents Chemother 2003;47:827-829.